Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nikole J. Byrne et al. BTS 2017;j.jacbts

Published byDavid Ricard Modified over 5 years ago

Similar presentations

Presentation on theme: "Nikole J. Byrne et al. BTS 2017;j.jacbts"— Presentation transcript:

1 Nikole J. Byrne et al. BTS 2017;j.jacbts.2017.07.003
Improved In Vivo Cardiac Function in Empagliflozin-Treated Mice With Heart Failure Is Preserved Ex Vivo Hearts from vehicle- and Empa-treated mice with HF were perfused ex vivo to measure cardiac function. Cardiac output (A), cardiac work (B), and heart rate (C) were measured using ex vivo perfused working hearts (n = 9 to 10). Results are mean ± SEM. *p < 0.05 versus vehicle, using Mann-Whitney U test. Abbreviations as in Figure 1. Nikole J. Byrne et al. BTS 2017;j.jacbts 2017 The Authors

Download ppt "Nikole J. Byrne et al. BTS 2017;j.jacbts"

Similar presentations

Daniel J. Lenihan et al. BTS 2016;1:

Daniel J. Lenihan et al. BTS 2016;1:
Muhammad Ali et al. BTS 2016;1:

Muhammad Ali et al. BTS 2016;1:
Céline Jumeau et al. BTS 2016;j.jacbts

Céline Jumeau et al. BTS 2016;j.jacbts
Mirnela Byku, and Douglas L. Mann BTS 2016;1:95-106

Mirnela Byku, and Douglas L. Mann BTS 2016;1:95-106
Mirnela Byku, and Douglas L. Mann BTS 2016;1:95-106

Mirnela Byku, and Douglas L. Mann BTS 2016;1:95-106
In vivo reconstitution of AP activity in MASP-1/3−/− mice with rMASP-3

In vivo reconstitution of AP activity in MASP-1/3−/− mice with rMASP-3
Vesna Nikolova-Krstevski et al. BTS 2017;2:

Vesna Nikolova-Krstevski et al. BTS 2017;2:
Hui-Fang Song et al. BTS 2017;2:

Hui-Fang Song et al. BTS 2017;2:
Hui-Fang Song et al. BTS 2017;2:

Hui-Fang Song et al. BTS 2017;2:
TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.
FIP200 deficiency alters mitochondria activation and ROS production in T cells. FIP200 deficiency alters mitochondria activation and ROS production in.

FIP200 deficiency alters mitochondria activation and ROS production in T cells. FIP200 deficiency alters mitochondria activation and ROS production in.
Juan J. Russo et al. JACC 2019;73:

Juan J. Russo et al. JACC 2019;73:
Heloise Mongue-Din et al. BTS 2017;2:

Heloise Mongue-Din et al. BTS 2017;2:
Jason A. Bartos et al. BTS 2016;j.jacbts

Jason A. Bartos et al. BTS 2016;j.jacbts
Rachel Truitt et al. BTS 2018;3:

Rachel Truitt et al. BTS 2018;3:
Helena M. Viola et al. BTS 2018;3:

Helena M. Viola et al. BTS 2018;3:
Helena M. Viola et al. BTS 2018;3:

Helena M. Viola et al. BTS 2018;3:
Nikole J. Byrne et al. BTS 2017;j.jacbts

Nikole J. Byrne et al. BTS 2017;j.jacbts
Helena M. Viola et al. BTS 2018;3:

Helena M. Viola et al. BTS 2018;3:
Everolimus Silences E2F Target Genes Through TERT-Dependent Epigenetic Histone Modification (A) Western blotting for MCM7 in WT and TERTtg mSMC treated.

Everolimus Silences E2F Target Genes Through TERT-Dependent Epigenetic Histone Modification (A) Western blotting for MCM7 in WT and TERTtg mSMC treated.

Similar presentations

Ads by Google